In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Report from the ESC Working Group on Thrombosis Young Researchers

The progress of the coronavirus pandemic has entered a new phase in which cautious unlocking in response to ever increasing numbers of vaccinated individuals is chased by fears of new variants and waning immunity. Research activities carried out by young thrombosis researchers continue to recover. Laboratories have now largely been opened back up and a shift of priority away from solely COVID-19 work has been observed.



In our own field of experimental clinical research, which relies on hospital co-operation and space, things continue to be challenging. As well as the demand on hospital space for the treatment of coronavirus patients that has affected the provision of many specialist services, clinical research facilities have often been requisitioned for COVID-19 vaccine studies, meaning non-COVID work has to some extent been side-lined. Slowly this is improving, however, particularly given the fact that cardiovascular deaths are once again outweighing coronavirus deaths. We, of course, must remember that we were already fighting other global pandemics of cardiovascular, metabolic and malignant disease when COVID-19 struck and should regain focus on these as normality gradually returns. 

The ESC Working Group on Thrombosis Young Researchers has continued to disseminate news and facilitate networking through such schemes as our Facebook group and "Paper of the Month". As "in person" conferences become more likely going into 2022, we hope to meet up once again.